期刊
APPLIED PHYSIOLOGY NUTRITION AND METABOLISM
卷 32, 期 4, 页码 619-634出版社
CANADIAN SCIENCE PUBLISHING
DOI: 10.1139/H07-034
关键词
polyunsaturated fatty acids; omega 3 fatty acids; alpha-linolenic acid; eicosapentaenoic acid; docosahexaenoic acid; desaturase; linoleic acid; arachidonic acid; heart disease; neurodegenerative diseases
There is considerable interest in the potential impact of several polyunsaturated fatty acids (PUFAs) in mitigating the significant morbidity and mortality caused by degenerative diseases of the cardiovascular system and brain. Despite this interest, confusion surrounds the extent of conversion in humans of the parent PUFA, linoleic acid or a-linolenic acid (ALA), to their respective long-chain PUFA products. As a result, there is uncertainty about the potential benefits of ALA versus eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA). Some of the confusion arises because although mamals have the necessary enzymes to make the long-chain PUFA from the parent PUFA, in vivo studies in humans show that z 5% of ALA is converted to EPA and <0.5% of ALA is converted to DHA. Because the capacity of this pathway is very low in healthy, nonvegetarian humans, even large amounts of dietary ALA have a negligible effect on plasma DHA, an effect paralleled in the omega 6 PUFA by a negligible effect of dietary linoleic acid oil plasma arachidonic acid. Despite this inefficient conversion, there are potential roles in human health for ALA and EPA that could be independent of their metabolisin to DHA through the desaturation-chain elongation pathway.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据